tradingkey.logo
tradingkey.logo

Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)

ReutersMar 16, 2026 12:13 PM

- Cogent Biosciences Inc COGT.O:

  • COGENT BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM)

  • COGENT BIOSCIENCES: BEZUCLASTINIB PDUFA TARGET ACTION DATE SET FOR DEC 30, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI